Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study

Figures & data

Figure 1 Patient disposition.

Table 1 Baseline characteristics (FAS)

	Galantamine (n = 110)	Donepezil (n = 108)	P-value
Age (mean ± SD), years	73.3 ± 8.5	74.0 ± 8.4	0.609
Distribution, n (%)			0.556
<65 years	15 (14)	20 (19)
65–85 years	91 (83)	83 (77)
>85 years	4 (4)	5 (5)
Sex, n (%)			0.591
Male	54 (49)	49 (45)
Female	56 (51)	59 (55)
Duration of cognitive impairment (mean ± SD), years	3.0 ± 2.2	3.3 ± 2.6	0.276
Duration of AD (mean ± SD), years	0.7 ± 1.3	0.7 ± 1.1	0.930
MMSE score	18.8 ± 3.8	17.9 ± 4.1	0.089
ADAS-cog/11	22.5 ± 9.3	23.3 ± 9.6	0.542
Prior use of cholinergic drugs, n (%)a	23 (21)	30 (28)	0.122

Note:

a All patients receiving cholinergic drugs at screening underwent a 4-week washout period.

Abbreviations: AD, Alzheimer’s disease; ADAS-cog/11, Alzheimer’s Disease Assessment Scale – cognitive subscale; FAS, full analysis set; MMSE, Mini-Mental State Examination; SD, standard deviation.

Figure 2 Mean change from baseline in Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog/11) score.

Note: *P < 0.05 vs baseline.

Table 2 Mean scores on the six ADAS-cog/11 functional areas at baseline and week 16

	Galantamine (n = 110)	Donepezil (n = 108)	P-value
Operation
Baseline	2.8 ± 2.2	2.8 ± 2.0
Week 16	1.9 ± 2.1	2.0 ± 2.0	0.883
Memory
Baseline	11.0 ± 4.0	11.4 ± 4.2
Week 16	8.5 ± 4.2	9.6 ± 4.6	0.430
Orientation
Baseline	2.9 ± 1.7	3.4 ± 2.0
Week 16	2.4 ± 2.0	3.0 ± 2.2	0.449
Visual space
Baseline	1.3 ± 0.9	1.3 ± 1.1
Week 16	2.4 ± 2.0	3.0 ± 2.2	0.420
Language
Baseline	2.8 ± 2.9	2.8 ± 3.0
Week 16	1.8 ± 2.5	2.3 ± 2.9	0.035
Attention
Baseline	2.8 ± 2.2	2.9 ± 2.2
Week 16	2.0 ± 2.2	2.2 ± 2.2	0.579

Abbreviation: ADAS-cog/11, Alzheimer’s Disease Assessment Scale – cognitive subscale.

Figure 3 Percentage of patients with an improvement from baseline of >0, >4, >7, and >10 points on the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog/11).

Note: *P < 0.05 vs donepezil.

Table 3 Adverse events occurring in ≥3% of subjects in either treatment arm

Adverse event, n (%)	Galantamine (n = 116)	Donepezil (n = 117)
Any adverse event	51 (44)	54 (47)
Nausea	15 (13)	25 (22)
Vomiting	7 (6)	11 (9)
Dizziness	8 (7)	9 (8)
Anorexia	3 (3)	7 (6)
Diarrhea	4 (3)	4 (3)
Sinus bradycardia	2 (2)	4 (3)
Belching	1 (1)	3 (3)
Premature contraction	3 (3)	0
Urinary tract infection	3 (3)	1 (1)